FN2 Earnings Intelligence
Gilead Sciences, Inc. ratios (quarterly)
Gilead Sciences, Inc. (GILD) Ratios (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $7,926 | $5,144 | $7,330 | $7,628 | $3,179 | - | - |
| + Debt | $24,952 | $24,946 | $24,941 | $22,174 | $26,246 | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $6,667 | $7,082 | $7,769 | $6,960 | $7,803 | $7,759.9 | $8,125.8 |
| % Growth | - | - | - | - | - | -0.1% | - |
| Gross Profit | $5,127 | $5,581 | $6,200 | $5,515 | $6,224 | - | - |
| % Margin | 76.9% | 78.8% | 79.8% | 79.2% | 79.8% | - | - |
| EBITDA | $2,334 | $2,567 | $3,417 | $2,679 | -$10,296 | - | - |
| % Margin | 35.0% | 36.2% | 44.0% | 38.5% | -131.9% | - | - |
| Net Income | $1,315 | $1,960 | $3,052 | $2,021 | -$10,496 | - | - |
| % Margin | 19.7% | 27.7% | 39.3% | 29.0% | -134.5% | - | - |
| Diluted EPS | $1.04 | $1.56 | $2.43 | $1.61 | -$8.45 | $2.12 | $2.14 |
| % Growth | - | - | - | - | - | -12.9% | - |
| Operating Cash Flow | $1,757 | - | - | $2,544 | - | - | - |
| CapEx | $104 | - | - | $117 | - | - | - |
| Free Cash Flow | $1,653 | - | - | $2,427 | - | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 | 9/30/2026 est. | 12/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $6,667 | $7,082 | $7,769 | $6,960 | $7,803 | $7,759.9 | $8,125.8 |
| Gross Profit | $5,127 | $5,581 | $6,200 | $5,515 | $6,224 | - | - |
| EBITDA | $2,334 | $2,567 | $3,417 | $2,679 | -$10,296 | - | - |
| Net Income | $1,315 | $1,960 | $3,052 | $2,021 | -$10,496 | - | - |
| Diluted EPS | $1.04 | $1.56 | $2.43 | $1.61 | -$8.45 | $2.12 | $2.14 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $7,926 | $5,144 | $7,330 | $7,628 | $3,179 |
| Short-term Debt | $2,806 | $2,806 | $2,806 | $1,313 | $2,414 |
| Long-term Debt | $22,146 | $22,140 | $22,135 | $20,861 | $23,832 |
| Total Debt | $24,952 | $24,946 | $24,941 | $22,174 | $26,246 |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $1,757 | - | - | $2,544 | - |
| Capital Expenditure | $104 | - | - | $117 | - |
| Free Cash Flow | $1,653 | - | - | $2,427 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 76.9% | 78.8% | 79.8% | 79.2% | 79.8% |
| EBITDA Margin | 35.0% | 36.2% | 44.0% | 38.5% | -131.9% |
| Net Margin | 19.7% | 27.7% | 39.3% | 29.0% | -134.5% |
| FCF Margin | 24.8% | - | - | 34.9% | - |
| Diluted EPS Growth | - | - | - | - | - |